Technical Analysis for IDXG - Interpace Diagnostics Group, Inc.

Grade Last Price % Change Price Change
B 8.3 7.37% 0.57
IDXG closed up 7.37 percent on Friday, April 9, 2021, on 29 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical IDXG trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Older End-of-Day Signals for IDXG ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 2 days ago
Down 1% 2 days ago
New 52 Week High 2 days ago
Up 5% 2 days ago
Up 1 ATR 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Interpace Diagnostics Group, Inc. Description

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment's services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Life Sciences Biology Supply Chain Management Gastrointestinal Healthcare Providers Medical Genetics Thyroid Diagnostic Tests Medical Management Gastrointestinal Cancer Product Lifecycle Qiagen Gastrointestinal Cancers Genotype Thyroid Nodule Thyroid Nodules

Is IDXG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.5
52 Week Low 2.58
Average Volume 186,640
200-Day Moving Average 4.21
50-Day Moving Average 4.96
20-Day Moving Average 5.65
10-Day Moving Average 6.28
Average True Range 0.65
ADX 27.09
+DI 40.80
-DI 10.15
Chandelier Exit (Long, 3 ATRs ) 6.55
Chandelier Exit (Short, 3 ATRs ) 6.15
Upper Bollinger Band 7.92
Lower Bollinger Band 3.38
Percent B (%b) 1.08
BandWidth 80.21
MACD Line 0.79
MACD Signal Line 0.47
MACD Histogram 0.3236
Fundamentals Value
Market Cap 33.55 Million
Num Shares 4.04 Million
EPS -0.49
Price-to-Earnings (P/E) Ratio -17.11
Price-to-Sales 0.47
Price-to-Book 7.62
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.80
Resistance 3 (R3) 9.70 9.10 9.55
Resistance 2 (R2) 9.10 8.72 9.15 9.47
Resistance 1 (R1) 8.70 8.48 8.90 8.80 9.38
Pivot Point 8.10 8.10 8.20 8.15 8.10
Support 1 (S1) 7.70 7.72 7.90 7.80 7.22
Support 2 (S2) 7.10 7.48 7.15 7.13
Support 3 (S3) 6.70 7.10 7.05
Support 4 (S4) 6.80